including antibiotic use and offending organisms. We compared the cumulative incidence of reinfection between those with or without suppression using a competing risk model, with death and revision for mechanical failure as competing risks.
Background. Parechovirus (PeV), specifically Parechovirus A type 3 (PeV-A3), is a picornavirus associated with severe infection in young infants, with disease manifestations ranging from undifferentiated fever, to sepsis like illness, and meningoencephalitis. There are limited data regarding long-term outcomes of infected infants. The objective of this study was to describe early childhood outcomes following infantile PeV-CNS infection Methods. Families of Infants hospitalized during 2014 with laboratory confirmed PeV-CNS infection were contacted for neurodevelopmental follow-up. Testing included medical history, standard neurologic examination, parental completion of Ages and Stages questionnaire (ASQ) and determination of Bayley III cognitive, motor, and language quotients. Neurodevelopmental impairment (NDI) was considered present if cognitive, motor, or language quotients were >1 standard deviation (mild) or >2 SD (severe) below the testing norms, the presence of cerebral palsy (CP), or sensory (vision/hearing) impairment. Relationship of childrens' outcomes to severity of PeV disease (uncomplicated febrile illness [mild], disseminated disease [moderate] or advanced disease requiring intensive care [severe]) was assessed by chi-square analysis.
Results. Nineteen children were available for testing at approximately 3 years of age (31-38 months), 12 (63%) with mild, five (26%) moderate, and two (11%) with severe disease. Mean Bayley quotients were within normal limits (see table) , one infant had mild CP (5%) and two (11%) had mild NDI. There was no apparent relationship of NDI with infant PeV clinical presentation. ASQ results included 11% at referral level and 32% suspect, and were unrelated to severity of the viral illness. However, all parents of children with moderate or severe presentations of infantile PeV disease had medical or behavior concerns at 3 years of age compared with 25% of those with mild presentation (P = 0.007). Background. ICD-9 codes have been widely used in studies utilizing large national databases that evaluate the clinical epidemiology of encephalitis in the United States. Many studies have showed that ICD-9 codes have poor accuracy in stroke, multiple sclerosis and pulmonary fibrosis but their utility in encephalitis is unknown.
Methods. Retrospective study of all adults with a discharge diagnosis of encephalitis by an ICD-9 code. The study was performed in 17 hospitals from the Memorial Hermann Hospital and Harris Health Hospital system in the Greater Houston area from March 2010 until July 2015. Medical records were reviewed and a case was considered accurately classified as encephalitis if they met the definition established by the international encephalitis consortium.
Results. A total of 1,241 cases were identified by a discharge diagnosis of ICD-9 code as having encephalitis. The most common cause identified was not having a central nervous system infection in 580 (46.7%) patients. A total of 244 (19.6%) patients were correctly identified as having encephalitis. Other causes identified were nosocomial meningitis (11.9%), community-acquired bacterial meningitis (8.1%), aseptic meningitis (5.8%), fungal meningitis (5.4%), tuberculosis (2.0%), and parasitic meningitis (0.2%).
Conclusion. ICD-9 codes have poor reliability in identifying patients with encephalitis questioning the accuracy of large nationwide studies that utilize them to identify patients. 
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No reported disclosures. Background. Neurosyphilis (NS) is an infection of the central nervous system caused by Treponema pallidum. Intramuscular (IM) penicillin (PCN) G procaine is a treatment option for those who cannot receive or decline intravenous (IV) therapy. Since August 24, 2016, it has been unavailable from the manufacturer, necessitating the use of IV PCN for NS. Our institutions organized a multidisciplinary, coordinated care system to expedite outpatient treatment of NS upon diagnosis. We report successful management of NS at an urban safety-net hospital in the post-procaine PCN era.
Neurosyphilis Management in the Post-Procaine Penicillin Era
Methods. We identified patients with suspected NS from the King County Public Health STD and Harborview Infectious Disease clinics from October 2016 to February 2018. Demographics, clinical symptoms, diagnostics, treatment, and outcomes were collected by chart review. Successful NS treatment was defined as resolution of cerebrospinal fluid (CSF) pleocytosis or elevated protein, improvement in neurologic symptoms or appropriate decrease in serum rapid plasma reagin (RPR) or CSF Venereal Disease Research Laboratory (VDRL) titers. Results. We identified 43 cases of suspected NS. The most common symptoms were blurred vision, headache, and tinnitus. All had a lumbar puncture (LP). Median days from LP to treatment initiation was 6-many starting on day of diagnosis. Fourteen patients (33%) required admission for treatment. Two patients declined therapy. IV PCN G was used in 93% of cases; one received IM ceftriaxone. Treatment was successful in 32 of 41 (78%) cases, with 23 of these (72%) managed as outpatients. Three cases were treatment failures for incomplete therapy adherence or equivocal response and uncertain diagnosis.
Conclusion. Without available IM procaine PCN, neurosyphilis is challenging to manage in vulnerable populations or those wishing to avoid inpatient admission. Employing a multidisciplinary, coordinated care approach can lead to successful treatment of NS using IV PCN in the outpatient setting.
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